Ellicott City, MD. – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced an expanded relationship with inVentiv Health, a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. As a Site Engagement Partner, inVentiv Health will continue to participate on the SCRS Global Impact Board, which works closely with SCRS’ Leadership Council to provide advice on strategic initiatives for SCRS. In addition, inVentiv Health will host two Site Advocacy Groups (SAGs) to gain access to the expertise and insights of SCRS members who have deep knowledge of operational and clinical hurdles that can impact trial conduct. “Investigational sites play an essential role in conducting successful clinical trials,” said Susan Stansfield, PhD, Executive Vice President, Clinical Division, inVentiv Health. “Through this expanded partnership, we will work together with sites to design enhanced processes and procedures to accelerate clinical trial effectiveness.” “inVentiv Health’s increased commitment to site collaboration with SCRS as a Site Engagement Partner is even more exciting because of their involvement through two SAGs,” said Christine Pierre, President of SCRS. “Continued growth in the SAG program and other multi-stakeholders programs affirms that inVentiv Health see SCRS’ commitment to site sustainability as essential to their own sustainability.” About SCRS SCRS is a global trade organization founded in 2012 which represents over 2,800 research sites in 42 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org. About inVentiv Health inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Our combined Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services, processes and integrated solutions that improve client performance. With more than 15,000 employees and the ability to support clients in more than 90 countries, our global scale and deep therapeutic expertise enable inVentiv to help clients successfully navigate an increasingly complex environment. For more information, visit inVentivHealth.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.